Key result
Bioresorbable polymer sirolimus-eluting stents resulted in similar rates of target lesion failure at 24 months compared to permanent polymer everolimus-eluting stents.
Why the study?
Does a bioresorbable polymer sirolimus-eluting stent improve clinical outcomes compared to a permanent polymer everolimus-eluting stent in patients with high-risk acute coronary syndromes?
RCT (n=264)
Single-blind
randomized
Yes
Does a bioresorbable polymer sirolimus-eluting stent improve clinical outcomes compared to a permanent polymer everolimus-eluting stent in patients with high-risk acute coronary syndromes?
Bioresorbable polymer sirolimus-eluting stents provide similar 24-month safety and efficacy outcomes compared to durable polymer everolimus-eluting stents in patients with high-risk acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Supports either stent choice in high-risk ACS without outcome differences; confirms comparable performance of bioresorbable versus permanent polymer platforms.
BACKGROUND: To investigate clinical outcomes of percutaneous coronary intervention using a sirolimus-eluting stent with bioresorbable polymer, Ultimaster (BP-SES) compared with a permanent polymer everolimus-eluting stent, Xience (PP-EES) in patients with high risk (ST-segment elevation and non-ST-segment elevation myocardial infarction) acute coronary syndromes (ACS) enrolled in the CENTURY II trial. METHODS: CENTURY II is a prospective, multicenter, randomized, single blind, controlled trial comparing BP-SES and PP-EES, with primary endpoint of target lesion failure (TLF) at 9month post-stent implantation. Out of 1123 patients enrolled in CENTURY II trial, 264 high risk ACS patients were included in this subgroup analysis, and the clinical outcomes including target lesion failure (TLF), target vessel failure (TVF), cardiac death, myocardial infarction, and stent thrombosis were evaluated at 24months. RESULTS: The baseline clinical, angiographic and procedural characteristics were similar between two groups. At 24months, TLF occurred in 6.3% of patients receiving a BP-SES and 6.5% of patients receiving a PP-EES (P=0.95); TVF was 6.3% in patients receiving a BP-SES and 9.4% in patients receiving a PP-EES (P=0.36). There were no significant differences in cardiac death, myocardial infarction and stent thrombosis rate. CONCLUSIONS: BP-SES achieved similar safety and efficacy outcomes as PP-EES in this ACS subgroup of CENTURY II study, at 24-month follow-up. This finding is hypothesis-generating and needs to be confirmed in larger trials with longer follow-up.
No takes yet. Share an insight, caveat, or question.
Díaz et al. (2016) conducted an RCT in High risk acute coronary syndromes (STEMI and NSTEMI) (n=264). Bioresorbable polymer sirolimus-eluting stent (BP-SES) vs. Permanent polymer everolimus-eluting stent (PP-EES) was evaluated on Target lesion failure (TLF) at 24 months (p=0.95). Bioresorbable polymer sirolimus-eluting stents resulted in similar rates of target lesion failure at 24 months compared to permanent polymer everolimus-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: